Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shire’s Vyvanse Approved For ADHD

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm will launch the drug in the second quarter pending final DEA clearance as a Schedule II controlled substance.

You may also be interested in...



ADHD Market Snapshot: Changes Blow In With Adderall XR Generics

The first generic versions of Shire's market-leading attention deficit/hyperactivity disorder medication Adderall XR (amphetamine extended release) are expected to hit the market April 1. This will deliver a kick to the remaining branded drugs in the category - though not as swiftly as some might expect

ADHD Market Snapshot: Changes Blow In With Adderall XR Generics

The first generic versions of Shire's market-leading attention deficit/hyperactivity disorder medication Adderall XR (amphetamine extended release) are expected to hit the market April 1. This will deliver a kick to the remaining branded drugs in the category - though not as swiftly as some might expect

FDA Approves Shire’s Once-daily Vyvanse For Adult ADHD

British biopharma had pegged nearly one-third of drug’s sales to off-label adult usage.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS065677

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel